Submandibular Gland Cancer: Symptoms, Diagnosis, and Treatment

Submandibular gland cancer is an uncommon but disproportionately aggressive form of salivary gland cancer that develops in the walnut-sized glands tucked beneath the jawline. Roughly 43% of tumors found in the submandibular gland turn out to be malignant, nearly double the rate seen in the parotid gland, the largest salivary gland. Because these cancers often present as painless lumps that feel benign, diagnosis can be delayed, and the prognosis is generally less favorable than for salivary cancers elsewhere in the head and neck. Understanding what to watch for, how the workup unfolds, and what treatment looks like can make a real difference in catching this disease early.

Why the Submandibular Gland Is a Higher-Risk Location

You have three pairs of major salivary glands: the parotid (in front of each ear), the sublingual (under the tongue), and the submandibular (beneath the jaw). Most salivary gland tumors occur in the parotid, and most of those are benign. The submandibular gland is different. Population-level data show that submandibular tumors carry a malignancy rate of about 42–43%, and the prognosis tends to be worse compared with parotid cancers at a similar stage.¹ Part of the reason is anatomy: the submandibular space is close to nerves, the floor of the mouth, and lymph node chains, giving cancer relatively easy access to structures that speed local and distant spread.

The most common malignant subtype found here is adenoid cystic carcinoma (ACC), which accounted for more than half of cancers in one surgical series.² ACC has a distinctive personality among cancers: it grows slowly, tends to invade along nerves, and has a notorious habit of sending distant metastases years or even decades after the original tumor is treated. Other subtypes seen in the submandibular gland include mucoepidermoid carcinoma, adenocarcinoma not otherwise specified, salivary duct carcinoma, and carcinoma ex pleomorphic adenoma.

Symptoms and How the Cancer Typically Presents

The most common first sign is a firm, painless lump under the jaw. That simplicity is part of the problem: most people assume a lump in that area is a swollen lymph node or a blocked salivary duct, both of which are far more common. In surgical studies, the majority of patients with submandibular gland cancer showed no obvious clinical signs of malignancy at the time they first sought care.² Only a small fraction had features that tipped off clinicians before the tissue was examined under a microscope.

When the cancer is more advanced or involves nerves, additional symptoms can appear:

Numbness or tingling: along the lower lip, chin, or tongue, resulting from nerve invasion.
Pain: a dull ache in the jaw area, sometimes mistaken for a dental problem.
Difficulty swallowing or opening the mouth: if the tumor extends into the floor of the mouth.
Facial asymmetry: weakness on one side of the lower face if the marginal mandibular branch of the facial nerve is involved.
A lump that has been present for months and is slowly growing: malignant submandibular masses tend to enlarge gradually rather than appearing overnight.

None of these symptoms are unique to cancer. Salivary stones, chronic infections, and benign tumors can cause similar complaints. That overlap is exactly why any persistent submandibular mass that does not resolve within a few weeks warrants imaging and often a tissue sample.

Conditions That Mimic Submandibular Gland Cancer

Before a cancer diagnosis is confirmed, several benign conditions need to be ruled out. Chronic sialadenitis, the inflammation that builds up when a salivary stone repeatedly blocks the duct, is the most frequent cause of a firm submandibular lump. A variant called Küttner tumor (sclerosing sialadenitis) can produce a rock-hard mass that is almost indistinguishable from cancer on physical exam.³ Pleomorphic adenoma, the most common benign salivary tumor, also appears in the submandibular gland, though less frequently than in the parotid. Rarer mimics include schwannoma, a nerve sheath tumor that can look alarmingly similar to salivary cancer on frozen section during surgery.⁴ These look-alikes reinforce the need for careful tissue diagnosis before committing to extensive surgery.

Risk Factors

Salivary gland cancers as a group are rare enough that pinning down specific risk factors has been difficult. The best evidence comes from case-control studies, and the associations are often modest.

Radiation exposure to the head and neck is the most consistently identified risk factor. Older therapeutic radiation treatments and early dental X-rays, particularly those performed before the mid-1950s when doses were substantially higher, have been linked to roughly a two- to three-fold increase in risk.⁵ Occupational exposure to radiation or radioactive materials, as well as exposure to nickel compounds, showed elevated risk in that same study. In men, heavy alcohol use and current smoking were associated with about a two-fold increase, though those links were weaker in women.

A Canadian case-control study found that eating four or more servings of processed meat per week was associated with a roughly 60% higher odds of salivary gland cancer, while higher intake of vegetables appeared to be modestly protective.⁶ These dietary links are suggestive but not definitive. Higher education and regular physical activity trended toward lower risk in the same study, though neither reached statistical significance. Overall, for most people diagnosed with submandibular gland cancer, no clear modifiable cause can be identified.

How the Diagnosis Is Made

Diagnosis usually begins with imaging and moves to tissue sampling. The two goals are: figure out whether the mass is likely malignant, and get enough tissue to determine the exact tumor type, since treatment depends heavily on subtype and grade.

Imaging

Ultrasound is typically the first imaging study because it’s quick, cheap, and noninvasive. CT and MRI offer more detail about how far the tumor extends, particularly into surrounding soft tissue, nerves, or bone. A meta-analysis pooling data across multiple imaging modalities found that MRI had the highest combined sensitivity and specificity for distinguishing benign from malignant salivary tumors, with a pooled sensitivity of about 80% and specificity of 90%.⁷ PET/CT performed similarly. A separate study comparing CT, MRI, and ultrasound head-to-head in salivary tumors found no statistically significant difference among the three in correctly identifying malignancy, suggesting that each has a role depending on the clinical scenario.⁸ In practice, many patients get both an ultrasound and either a CT or MRI so that surgeons can plan the operation.

Tissue Sampling

Fine-needle aspiration (FNA) has been the traditional first step for obtaining cells from a salivary mass. A thin needle draws out a small sample, which a pathologist examines. It’s safe and can be done in the clinic. The drawback is that FNA has a meaningful rate of inconclusive results, around 19% in one series, and a lower sensitivity for catching malignancy compared with core needle biopsy (CNB).⁹ CNB uses a slightly larger needle to retrieve a sliver of intact tissue, preserving the architecture pathologists need to determine exact tumor type. A direct comparison found that CNB detected malignancy with nearly 90% sensitivity versus about 58% for FNA.¹⁰ A systematic review and meta-analysis confirmed that CNB produces significantly fewer nondiagnostic results and higher pooled sensitivity and specificity than FNA for salivary gland tumors.¹¹ Despite this, FNA remains widely used as an initial screen, with CNB reserved for inconclusive cases or when the subtype determination is critical for surgical planning.

Staging and the Role of Lymph Nodes

Staging follows the standard TNM system for major salivary glands, which accounts for tumor size (T), lymph node involvement (N), and distant metastases (M). Among these, lymph node status is one of the strongest drivers of outcome. A large population-based analysis found that about 42% of submandibular gland cancer patients had lymph node metastases, and having three or more involved nodes carried a dramatically worse prognosis.¹² The ratio of positive to total examined lymph nodes also mattered: patients with a high ratio had the greatest risk of dying from their disease.

High-grade tumors are far more likely to harbor lymph node metastases than low-grade ones. A study examining the pattern of nodal spread found that all patients with clinically positive nodes had pathologically confirmed metastases, and even among those whose imaging showed no suspicious nodes, roughly one in five with high-grade tumors had occult (hidden) metastases found after surgery.¹³ No patients with low-grade tumors had nodal metastases in that series, suggesting that tumor grade is an important factor in deciding how aggressively to address the neck.

Surgery

The backbone of treatment is surgical removal of the submandibular gland along with the tumor. For malignant tumors, this means excising the entire gland and a margin of surrounding tissue. The question of how far to extend the operation into the neck is one of the more debated areas. If imaging or physical exam shows suspicious lymph nodes, a neck dissection to remove them is standard. Whether to perform an elective neck dissection when no nodes appear involved remains controversial.¹⁴ For high-grade tumors, many surgeons lean toward doing it because of the meaningful rate of occult metastases discussed above. For low-grade tumors, observation with close follow-up imaging is often considered adequate.

The primary nerve at risk during this surgery is the marginal mandibular branch of the facial nerve, which runs near the lower border of the jaw and controls the muscles around the lower lip and chin. Temporary weakness of this nerve occurs in roughly 10–16% of cases, while permanent injury is less common, around 1–2%.¹⁵ When a full neck dissection is performed, the injury rate can be higher, with one study reporting about 18% of patients showing some degree of marginal mandibular nerve impairment after neck dissection, which affected their ability to smile symmetrically and the appearance of the lower lip.¹⁶ The lingual nerve and hypoglossal nerve (which controls tongue movement) can also be injured, though less frequently.

Robotic-assisted approaches have been explored for submandibular gland cancer surgery, offering the potential for smaller external incisions and better cosmetic outcomes. Early reports describe the approach as feasible in selected cases with good functional results, though it remains far from standard practice.¹⁷

Radiation Therapy

Radiation is most commonly used after surgery (adjuvant radiation) rather than as the sole treatment. Postoperative radiation is generally recommended for larger tumors, close or positive surgical margins, bone invasion, perineural invasion, and recurrent disease.¹⁸ With adjuvant radiation, long-term locoregional control rates can reach about 88–90% at five and ten years.¹⁹

A question patients often ask is how quickly radiation needs to start after surgery. A single-institution study with a median follow-up of over eight years found no statistically significant difference in overall survival or locoregional recurrence-free survival when patients were stratified by the time between surgery and the start of radiation.²⁰ That’s somewhat reassuring for patients who need a few extra weeks to recover before beginning radiation, though most centers still aim to start within a reasonable window.

Proton beam therapy has generated growing interest, especially for adenoid cystic carcinoma, because protons can deliver a high dose to the tumor while sparing more of the surrounding normal tissue compared with conventional photon radiation. For ACC specifically, a series of 106 patients treated with proton therapy reported five-year locoregional control of about 89% overall, rising to 93% in the group that received protons after surgery.²¹ Across the broader literature on particle therapy for ACC, five-year local control rates range from roughly 65% to 90%, with survival ultimately limited more by distant metastases than by local recurrence.²² Side effects of proton therapy are generally mild and include skin inflammation, mucositis, and dry mouth. A small but real risk of temporal lobe injury has been reported in about 4% of patients in one ACC-specific series.

Systemic and Targeted Therapies

Chemotherapy has historically played a limited role in salivary gland cancers, but the landscape is shifting. For patients with inoperable or metastatic disease, systemic therapy is the primary option, and several targeted approaches have shown promise based on the molecular profile of the tumor.²³

Salivary duct carcinoma, a high-grade subtype, frequently overexpresses HER2 (similar to some breast cancers) or the androgen receptor. In HER2-positive tumors, HER2-targeted therapy has become a standard treatment option. When disease progresses despite initial HER2-targeted treatment, newer antibody-drug conjugates have shown efficacy. For androgen receptor-positive tumors, hormonal therapy using androgen deprivation has demonstrated activity.²⁴ Immunotherapy with checkpoint inhibitors is also being studied, though response rates in salivary gland cancers have generally been modest. The era of “one chemo fits all” is giving way to treatment matched to the specific molecular features of the tumor, which is particularly relevant given how many distinct subtypes arise in the submandibular gland.

Prognosis and Long-Term Outlook

Survival figures for submandibular gland cancer vary depending on the series, the mix of tumor subtypes, and how advanced the disease is at diagnosis. A multicenter study reported five-year overall survival of about 66% and ten-year overall survival of about 57%, with disease-specific survival (meaning death specifically from the cancer) at roughly 77% and 72% at those time points.²⁵ Older single-institution data show crude five-year survival around 50% and ten-year survival around 36%, underscoring the long tail of this disease.²⁶

The factors that most consistently predict outcome include T stage (tumor size and local extent), N stage (nodal involvement), tumor grade, and the presence of perineural invasion.²⁵ Advanced T stage (T3–T4) and a high lymph node ratio are independent risk factors for worse disease-free survival, distant metastasis-free survival, and overall survival.²⁷

Distant metastases are the main threat in the years after treatment. Lungs are the most common site, followed by bones and liver.²⁶ ACC is especially known for late distant recurrence, with some patients developing metastases a decade or more after their initial treatment. One review noted that most patients with ACC die five to ten years after initial treatment, often from metastatic disease.²⁸ This protracted course means follow-up imaging and monitoring need to continue for many years, not just the typical five-year mark used for many other cancers.

Dry Mouth and Quality of Life After Treatment

Radiation to the head and neck frequently causes xerostomia, or chronic dry mouth, which affects eating, speaking, and dental health. Because the submandibular glands produce a large share of resting saliva, losing one or both to surgery and then having radiation delivered nearby can make this side effect worse. Techniques to preserve salivary function have improved considerably. Intensity-modulated radiation therapy (IMRT) allows the radiation dose to be sculpted around sensitive structures. In one study combining submandibular gland transfer (physically moving the remaining gland out of the radiation field) with IMRT, about 89% of patients had absent or only mild dry mouth a year after radiation, and salivary flow was preserved at roughly three-quarters of pre-treatment levels.²⁹ While that particular study addressed head and neck cancer broadly and not submandibular gland cancer specifically, it illustrates how preservation strategies can meaningfully reduce the burden of treatment.

Submandibular Gland Cancer in Children and Adolescents

Salivary gland malignancies are rare in children, and when they do occur, the submandibular gland accounts for a small minority of cases. A review of 113 pediatric salivary gland malignancies found only 10 in the submandibular gland, with a mean age at presentation of about 13 years. None of the submandibular cases in that series were fatal.³⁰ More broadly, five- and ten-year overall survival rates for pediatric salivary gland cancers range between 80% and 95%, and prognosis is generally favorable when the tumor is caught early, is low-grade, and can be removed with clear margins.³¹ An Italian series of 17 pediatric patients with salivary gland carcinomas found that most were low-grade with favorable presentations, and only one patient, who had a large high-grade tumor, died of disease.³² Surgical excision remains the mainstay of treatment in children, with radiation reserved for high-risk features, because of the added concern about long-term side effects from radiation in growing bodies.

Using the Remaining Gland for Reconstruction

An intriguing surgical development involves using a healthy submandibular gland as a reconstructive flap. In patients undergoing surgery for oral cancers near the submandibular region, surgeons have used the gland, along with its blood supply, to fill defects left by tumor removal. A series of 15 patients who received submandibular gland flaps to reconstruct defects after tongue, gingival, or floor-of-mouth cancer surgery showed good healing, excellent speech and swallowing function, and no local recurrence in the flap-repaired area during follow-up.³³ This approach is not applicable to submandibular gland cancer itself, since the gland is the diseased organ being removed, but it underscores how surgeons are rethinking the value of this small gland in head and neck reconstruction more broadly.

1
JAMA Network. Epidemiology, Prognostic Factors, and Treatment of Malignant Submandibular Gland Tumors: A Population-Based Cohort Analysis
2
PubMed Central / Wiley Online Library. Submandibular gland cancer: Specific features and treatment considerations
3
PubMed. Dynamic contrast-enhanced ultrasound for differential diagnosis of submandibular gland disease
4
PubMed Central. Microcystic/Reticular Schwannoma Arising in the Submandibular Gland: A Rare Benign Entity that Mimics More Common Salivary Gland Carcinomas
5
PubMed. Environmental factors and the risk of salivary gland cancer
6
PubMed Central. A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada
7
PubMed. The diagnostic role of ultrasonography, computed tomography, magnetic resonance imaging, positron emission tomography/computed tomography, and real-time elastography in the differentiation of benign and malignant salivary gland tumors: a meta-analysis
8
PubMed Central. Neither MRI, CT nor US is superior to diagnose tumors in the salivary glands – an extended case study
9
American Journal of Neuroradiology. Comparison of Fine-Needle Aspiration and Core Needle Biopsy under Ultrasonographic Guidance for Detecting Malignancy and for the Tissue-Specific Diagnosis of Salivary Gland Tumors
10
Journal of Pathology and Translational Medicine. Accuracy of Core Needle Biopsy Versus Fine Needle Aspiration Cytology for Diagnosing Salivary Gland Tumors
11
PubMed. Comparison of core needle biopsy and fine-needle aspiration in diagnosis of malignant salivary gland neoplasm: Systematic review and meta-analysis
12
PLOS ONE. Number and ratio of metastatic lymph nodes impacts the prognosis of submandibular gland cancer
13
PubMed Central. Incidence and spread pattern of lymph node metastasis from submandibular gland cancer
14
PubMed Central. Neck dissection for salivary gland malignancies
15
PubMed Central. Submandibular Gland Surgery: Our Clinical Experience
16
PubMed. Marginal mandibular nerve injury during neck dissection and its impact on patient perception of appearance
17
PubMed. Robotic-assisted neck dissection in submandibular gland cancer: preliminary report
18
International Journal of Radiation Oncology, Biology, Physics. Postoperative and Primary Radiotherapy for Salivary Gland Carcinomas: Indications, Techniques, and Results
19
PubMed. Postoperative radiotherapy for malignant tumors of the submandibular gland
20
PubMed Central. Timing of postoperative radiation therapy and survival in resected salivary gland cancers: long-term results from a single institution
21
PubMed Central. The Use of Proton Radiation in the Management of Adenoid Cystic Carcinoma
22
PubMed Central. The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck
23
PubMed Central. Targeted Therapy, Chemotherapy, Immunotherapy and Novel Treatment Options for Different Subtypes of Salivary Gland Cancer
24
Cancer Treatment Reviews. Submandibular Gland Cancer: Symptoms, Diagnosis, and Treatment
25
PubMed. Long-term outcomes and prognosis in submandibular gland malignant tumors: A multicenter study
26
Cancer. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors
27
PubMed Central. Lymph node ratio predictive of recurrence, distant metastasis, and survival in submandibular gland carcinoma patients
28
Clinical Case Reports. Adenoid cystic carcinoma of submandibular gland metastatic to great toes: case report and literature review
29
PubMed. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer
30
PubMed. Clinical characteristics and survival for major salivary gland malignancies in children
31
International Journal of Pediatric Otorhinolaryngology. Salivary gland malignancies in children
32
PubMed. Salivary gland carcinomas in children and adolescents: the Italian TREP project experience
33
PubMed Central. The preservation and application of the submandibular gland in oral squamous cell carcinoma